Verastem Names Michael Bailey as Next CEO

Company Verastem Oncology Event Type CEO Succession Modality Small molecules (RAF/MEK and FAK inhibition; KRAS G12D ON/OFF inhibitor) Asset AVMAPKI FAKZYNJA; VS-7375 Target RAF/MEK; FAK; KRAS G12D Disease Area Recurrent low-grade serous ovarian cancer; KRAS G12D-driven solid tumors Summary Verastem Oncology appointed director Michael P.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
GenScript Raises HK$2.33 Billion for AIDD Expansion
TriGemX Raises $94 Million for Phase 3 Migraine Trials